Amid increasing public scrutiny of rising insulin prices, some health insurers are taking matters into their own hands to help their diabetic members afford the lifesaving medications. Between 2012 and 2016, there was a rapid increase in total health care spending on people with type 1 diabetes, “driven primarily by gross spending on insulin that doubled over the period” — even though insulin use rose only modestly, according to a Health Care Cost Institute report released in January.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.